Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.
You may also be interested in...
Adalimumab-atto is approved for seven indications on the reference product label but lacks four others that are protected by orphan product exclusivity; launch timing is unclear due 'patent dance' litigation.
Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.
With preliminarily Zarxio data expected shortly, consortium of payers and sponsors is laying groundwork to monitor future biosimilar launches.